HTG Molecular Diagnostics, Inc. HTGM Open HTG Molecular Diagnostics, Inc. in new tab
HTG Molecular Diagnostics, Inc. Analysis (HTGM)
Is HTG Molecular Diagnostics, Inc. a good investment? HTG Molecular Diagnostics, Inc. (HTGM) is currently trading at 0.4800 USD.
Investor FAQ
Does HTG Molecular Diagnostics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is HTG Molecular Diagnostics, Inc.?
HTG Molecular Diagnostics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Dividends
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion